Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 807: 426c.Mod.Core-C4b Vaccine in PLWH With or Without ATI
NCT06006546Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of 426c.Mod.Core-C4b in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of participants with local reactogenicity signs and symptoms, Number of participants with systemic reactogenicity signs and symptoms and 8 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
426c.Mod.Core-C4b
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06006546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006546.